Core Viewpoint - The company Fuhong Hanlin (02696) has seen a significant stock price increase following the announcement that its innovative PD-1 inhibitor, H drug Surulitinib, has been officially included by the NMPA as a breakthrough therapy for gastric cancer treatment [1] Group 1: Company Developments - Fuhong Hanlin's H drug Surulitinib has been recognized as a breakthrough therapy by the NMPA for use in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer [1] - The phase 3 clinical study for the H drug targeting this indication has met its primary endpoint, potentially offering patients improved survival benefits and quality of life [1] Group 2: Market Context - As of the announcement date, there are currently no targeted PD-1 monoclonal antibody drugs approved globally for neoadjuvant/adjuvant treatment of gastric cancer [1] - According to the latest IQVIA MIDAS data, the global sales for targeted PD-1 monoclonal antibody drugs are projected to reach approximately $45.704 billion in 2024 [1]
复宏汉霖午后涨超6% 斯鲁利单抗近期获NMPA纳入突破性治疗品种